does hpv vaccine really lower your risk of cancer?

The HPV vaccine reduces your risk of the specific cancers caused by HPV 16 and 18, but the evidence is weaker than most people are told.

The claim that the vaccine cuts cervical cancer risk by about 70-80% comes from a narrative review [2], but that number is based on the proportion of cancers caused by HPV 16 and 18, not on a direct trial showing that many fewer cancers occurred. The original phase II trial of Gardasil reported zero cases of CIN 2/3 in the vaccine group versus 21 in the placebo group, and 1 cervical cancer versus 36 [5]. That sounds dramatic, but the sample was tiny and the follow-up short. The real-world picture is more complicated.

In Canada, cervical cancer rates in women aged 35-54 have been rising since 2001, not falling, despite the vaccine program [1]. In the U.S., incidence declined from 2000 to 2011 but then flattened, and the proportion of advanced-stage cancers (FIGO IV) actually increased from 10.1% to 15.5% [4]. These trends do not prove the vaccine failed, but they do not match the simple story of a 70-80% drop.

The vaccine also has a documented blind spot. A modeling study from 2012 predicted that suppressing HPV 16 and 18 could unmask other high-risk types, leading to an apparent 3-10% increase in cervical cancer from non-vaccine types [3]. That is not a conspiracy theory; it is a mathematical consequence of removing competition between viral types. A 2025 systematic review found one long-term study that reported negative vaccine effectiveness against non-preventable CIN2+ types, though other studies found cross-protection against HPV 31 [6]. The evidence is genuinely mixed.

The vaccine clearly prevents infection with HPV 16 and 18, and that should reduce some cancers. But the population-level data does not yet show the dramatic decline you would expect if the vaccine worked as advertised. The burden of proof has not been met for the claim that it "really lowers your risk of cancer" in a meaningful way for the average person.

My call: the HPV vaccine prevents some precancerous lesions, but the population data is inconsistent and the risk of type replacement is real. Confidence: moderate for preventing HPV 16/18 infection, low for a net reduction in all cervical cancer.